A shadow has fallen on recent evidence-based consensus statements for systemic sclerosis-associated ILD management which may have been developed with too much assistance from the pharmaceutical industry. In Correspondence to The Lancet Rheumatology, American and Australian rheumatologists including Dr Samuel Whittle and Associate Professor Philip Robinson said they were concerned the development process may have ...
Australian rheumatologists express concern about consensus statement bias
By Mardi Chapman
1 Jun 2020